Sex Differences in Angiotensin II-Induced Hypertension in Mice

Study Background and Research Question

Hypertension remains a major risk factor for cardiovascular morbidity and mortality worldwide. Epidemiological evidence has long indicated that men and women differ in both the incidence and severity of hypertension, implicating sex-dependent mechanisms in blood pressure (BP) regulation. Recent advances have focused on elucidating the contributions of sex hormones and their interactions with neurohumoral systems, such as the renin-angiotensin and autonomic nervous systems. However, the precise mechanisms underlying sex differences—particularly in angiotensin II (ANG II)-induced hypertension—remained incompletely understood in conscious animal models. The reference study, Sex differences in the development of angiotensin II-induced hypertension in conscious mice, addresses this gap through comprehensive physiological monitoring and targeted interventions in male and female mice.

Key Innovation from the Reference Study

The primary innovation of this research lies in the direct, comparative analysis of male and female mice subjected to chronic ANG II infusion, while maintaining animals in a conscious, freely moving state. This approach, leveraging telemetry-based BP and heart rate (HR) measurements, allows for accurate assessment of physiological responses without the confounding effects of anesthesia or restraint. Moreover, the study systematically evaluates the impact of gonadectomy (removal of gonadal sex hormones) in both sexes, providing mechanistic insight into the role of endogenous sex hormones in modulating hypertensive responses and autonomic regulation.

Methods and Experimental Design Insights

The experimental design is distinguished by several methodological strengths:

• Animal Preparation: Male and female mice underwent surgical implantation of telemetry devices for real-time, continuous measurement of aortic BP and HR.
• ANG II Infusion: Chronic systemic administration of ANG II was achieved via subcutaneously implanted osmotic pumps, delivering a controlled dose (800 ng·kg^-1·min^-1).
• Gonadectomy Models: To dissect the impact of sex hormones, cohorts of mice were subjected to gonadectomy (castration in males, ovariectomy in females) prior to infusion protocols.
• Autonomic Function Assessment: Baroreflex sensitivity was analyzed using phenylephrine-induced bradycardia, and the contribution of sympathetic tone was evaluated via ganglionic blockade.

This rigorous design enabled the isolation of sex-specific mechanisms in both basal and ANG II-induced hypertensive states, with particular attention to neuronal signaling and autonomic regulation.

Protocol Parameters

• ANG II dosage: 800 ng·kg^-1·min^-1 via subcutaneous osmotic pump for chronic infusion.
• Telemetry monitoring: Continuous aortic BP and HR measurement in conscious, freely moving mice.
• Gonadectomy timing: Performed prior to ANG II infusion to assess hormonal contributions.
• Ganglionic blockade: Applied at day 7 post-infusion to probe sympathetic contribution to BP maintenance.
• Baroreflex assessment: Phenylephrine-induced bradycardia slope measured before and during ANG II infusion.

Core Findings and Why They Matter

The study's data reveal several key observations:

• Baseline BP: Male and female mice showed similar baseline BP prior to ANG II treatment.
• Hypertensive Response: ANG II infusion elicited a much greater increase in BP in males (35.1 ± 5.7 mmHg) than in females (7.2 ± 2.0 mmHg), demonstrating a pronounced sex difference.
• Gonadectomy Effects: Removal of sex hormones attenuated ANG II-induced hypertension in males (15.2 ± 2.4 mmHg) and augmented it in females (23.1 ± 1.0 mmHg), indicating that androgens exacerbate and estrogens protect against hypertensive responses.
• Heart Rate Dynamics: Females exhibited higher baseline HR than males. ANG II infusion significantly decreased HR in females, but did not produce the expected baroreflex-mediated HR decrease in males or gonadectomized mice.
• Baroreflex Sensitivity: The slope of baroreflex bradycardia (response to phenylephrine) was blunted in males during ANG II infusion, but not in females, suggesting sex-specific resetting of autonomic reflexes.
• Sympathetic Contribution: Ganglionic blockade produced a greater BP reduction in males than females after ANG II infusion (−61.0 ± 8.9 vs. −36.6 ± 6.6 mmHg), implicating increased sympathetic activity in male hypertension pathophysiology.

These findings collectively indicate that male mice are more susceptible to ANG II-induced hypertension due to both hormonal and autonomic mechanisms, while female sex hormones confer significant protection. The results underscore the importance of incorporating sex as a biological variable in experimental hypertension and neuronal signaling pathway research. They also highlight the value of targeting autonomic regulation and nicotinic acetylcholine receptor signaling in mechanistic studies.

Comparison with Existing Internal Articles

Several internal articles expand on the implications of these findings for the broader research community. For example, Sex Differences in Angiotensin II-Induced Hypertension in Mice provides a detailed overview, reinforcing the mechanistic insights into sex hormone-mediated autonomic regulation. Similarly, Hexamethonium Bromide: Redefining Sex Differences in Hypertension explores how selective antagonists of neuronal-type nicotinic AChR can experimentally dissect autonomic ganglia contributions to hypertension. These resources align with the reference study’s approach in highlighting both the importance of autonomic neurotransmission and the need for rigorously validated reagents in autonomic nervous system studies and cholinergic neurotransmission inhibition workflows.

Limitations and Transferability

While this study provides robust evidence for sex differences in conscious mouse models, several limitations should be considered when extrapolating findings:

• Species Specificity: Mouse physiology may not fully recapitulate human hypertensive pathophysiology, particularly regarding hormonal and autonomic regulation.
• Chronic Infusion Model: The use of high-dose, chronic ANG II infusion may not precisely mimic clinical hypertension development in humans.
• Focus on Autonomic and Hormonal Mechanisms: Other contributors to sex differences in hypertension, such as renal or vascular factors, were not explicitly addressed.

Despite these considerations, the research offers a valuable preclinical framework for dissecting sex-specific mechanisms and has direct implications for the design of future studies in nicotinic acetylcholine receptor signaling and neuronal nicotinic acetylcholine receptor blocker applications.

Research Support Resources

To enable reproducible and mechanistic investigations of autonomic regulation and neuronal signaling in hypertension models, researchers may utilize rigorously validated reagents such as Hexamethonium Bromide (SKU B1592). As a selective antagonist of neuronal-type nicotinic AChR, this compound is instrumental in probing ganglionic contributions to blood pressure regulation and dissecting cholinergic neurotransmission in the autonomic nervous system. For detailed protocol guidance and application notes, refer to APExBIO’s product documentation, and consider integrating recommendations from Optimizing Neuronal AChR Studies with Hexamethonium Bromide (B1592).